Eagle Biosciences, Inc. is excited to partner with Idylle to bring you an exciting new variety of products!

Idylle is a unique company that is based in France. Their facilities include a state of the art tech transfer platform that works to bring innovation into life science workflows. They produce some of the most innovative R&D tools, side by side with researchers who design, test, and use them. Their products are easy to handle research tools that have been approved by the scientific community using Idylle’s unique ‘Test Programs’. These Test Programs are a four-week trial that allows researchers to test the products in their workflow and share their feedback.

We will be offering some of these products in a microscopy line that is intended to help improve your imaging needs. Check out the items below, and follow along in the upcoming weeks as we take a deep dive into each item.

Microscopy Products

Actiflash – Stable Tamoxifen-like photoactivable inducer.

Chitozen – The 1st functionalized microscope coverslip to image live bacteria

Everspark – Ready to use super-resolution microscopy buffer.

Stampwell – A family of stamps to democratise the 3D culture.

Stencell – The PDMS no-brainer solution for all micro-volume experiments, anywhere.

If you have a question about any of these products, or any of our other offerings, contact us here.

Eagle Biosciences, Inc. is continuing to work with BPM Biotech in the support the Fetuin A (PTM) ELISA (DNlite-DKD)!

About Fetuin A (PTM) ELISA

This Fetuin A (PTM) ELISA (DNLite-DKD) measures a unique biomarker that can have great impact on those with diabetic kidney disease (DKD). The Fetuin A post translation modifications (PRM) measured in this assay was identified in a large-scale profiling of urinary proteomics. This new biomarker can help predict the kidney condition of diabetes patients, months to years in advanced. This urine test can help predict kidney decline or complications and potentially improve a patient with diabetic kidney disease quality of care.

Check out the flyer below for a comprehensive look at this unique test!

Other Reference Materials

Instructions for Use
Acute Kidney Disease in the Outpatient Setting

If you have any questions about this product or any of our other offerings, contact us here.

Recent Study Finds Link Between Diet and Fitness on Mood and Stress Levels

A recent study’s results  propose that a peak day of the week may be associated with different mental stressors. Those who display higher physical fitness may relax faster during downtime. There is a potential robust link between diet and fitness on mood, stress levels, and time of the week. This suggests that customization of diet and lifestyle factors based on time of the week and fitness level may improve mood. Check out the full text and abstract below.


The purpose of the study was to assess the effect of diet quality and physical fitness on saliva cortisol, mood, and mental distress. These relationships were compared between a peak weekday (Wednesday) and a weekend day (Saturday) when mood may fluctuate. Methods: Forty-eight healthy college students participated in the study. Participants completed the Mood and Anxiety Symptom (MASQ) and Kessler Psychological Distress Scale 10 questionnaires on Wednesday and Saturday and recorded their diet for three days. Saliva was collected before and after a workout for cortisol extraction. Results: SA had significantly higher saliva cortisol levels post-workout but lower MASQ scores on Saturday (p < 0.05). There was a very significant association between MASQ scores on Wednesday (p = 0.005), which became less significant on Saturday. In addition, lower BMI values and high-fat consumption were associated with higher cortisol levels after exercise (p < 0.05). Conclusions: There is a strong link between dietary factors, cortisol levels, mood, and time of the week. In addition, our results suggest that saliva cortisol levels may not be directly linked to negative affect but are influenced by diet quality when mental distress exists. In addition, physical fitness may play a role in improving mood during weekends.

Begdache L., Sadeghzadeh S., Pearlmutter P., et al. Dietary Factors, Time of the Week, Physical Fitness and Salivary Cortisol: Their Modulatory Effect on Mental Distress and Mood. J Environ Res Public Health. 2022; 19(12):7001. 10.3390/ijerph19127001

Eagle Bioscience’s Kits are listed below:

Cortisol Saliva ELISA Assay Kit
Ultrasensitive Cortisol Saliva ELISA

If you have any questions about our Cortisol Saliva ELISA Assay Kits or our other offerings, contact us here.

Determination of IL-8 Levels May Posses Potential Prognostic and

Diagnostic Value in Thyroid Cancer Patients

A recent study’s data revealed that the determination of Bax, Bcl-2, IL-8, and TNF-α levels might possess a potential prognostic and diagnostic value in thyroid cancer patients, reflecting that apoptosis and inflammation are important mechanisms in thyroid cancer. These molecular findings were also supported by a series of histopathological and immunohistochemical findings that concluded that tissue TG and TTF1 could be accurate diagnostic factors in patients with thyroid carcinoma. Check out the full text and abstract below.


Thyroid cancer is among the most prevalent cancers with different types and stages. New markers are required for the prognosis and diagnosis of the disease. The present study aimed to detect the role of new markers, including galectin-3 (Gal-3) and thyroglobulin (TG), in the prognosis and staging of thyroid cancer. The study also investigated the potential apoptotic and inflammatory mechanisms involved in thyroid cancer through the determination of B-cell lymphoma 2 (Bcl-2), interleukin-8 (IL-8) and tumor necrosis factor   (TNF ) during the different stages of the cancer using a series of molecular methods. Histopathological and immunohistochemical examinations were also performed. A total of 300 subjects were classified into: 100 normal healthy subjects matched in age and sex, 100 patients with thyroid carcinoma stage I (T1N0M0) and 100 patients with thyroid carcinoma stage 2 (T2N1M1). Interestingly, the present study revealed a significant increase in the levels of TG and Gal-3 in thyroid cancer patients compared to the control group. Furthermore, the levels of Bcl-2, IL-8 and TNF-  significantly increased in the patient serum. The histopathological examination and immunohistochemical observations confirmed the molecular and hematological findings. Collectively, the present study concluded that serum TG and Gal-3 could be useful markers in the prognosis and staging of patients with thyroid cancer. Furthermore, the determination of Bax, Bcl-2, IL-8 and TNF-  levels constitute a major important marker for investigation of the mechanisms of apoptosis and inflammation in thyroid cancer. To our knowledge, this is the first study that used both galectin-3 and TG as tumor markers in the prognosis and differentiation between the different stages of cancer.

Okda T.M., Atwa G.M.K., Eldehn A.F., et al. A Novel Role of Galectin-3 and Thyroglobulin in Prognosis and Differentiation of Different Stages of Thyroid Cancer and Elucidation of the Potential Contribution of Bcl-2, IL-8 and TNF-α. Biomedicines 2022, 10(2), 352

Eagle Biosciences’ IL-8 Kits are listed below:

IL-8 Human ELISA Assay
Rat IL-8 ELISA Assay Kit
Mouse IL-8 ELISA Assay Kit

If you have any questions about our IL-8 ELISA Assay Kits or our other offerings, contact us here.

EagleBio Visits AACC in Atlanta Georgia

Eagle Biosciences will be at AACC in Chicago, Illinois!

This year AACC is in Chicago at the McCormick Place Convention Center, Sunday July 24th – Thursday July 28th. We will be at booth #315! Come by to learn about the GA-Map Dybiosis Test Lx and more assays that could help you with your microbiome or other research! We will be there to answer any questions you may have, or stop and say hi! We love seeing our customers!

Product Highlights

GA-Map Dysbiosis Test Lx: The first and only standardized solution for microbiome profiling! The GA-Map Dysbiosis Test Lx is a simple multiplex stool assay that maps the intestinal microbiota profile for a selected set of bacteria. The GA-map® platform uses probes that target variable regions (V3 to V7) of the bacterial 16S rRNA gene to characterize and identify bacteria present. The targets are identified in a molecular multiplex assay that utilizes the Single Nucleotide Primer Extension (SNuPE) technology patented by Professor Knut Rudi (US6617138). A unique algorithm takes advantage of all the data generated by the detection of the SnuPE products to determine dysbiosis level in the sample. The algorithm is incorporated in the GA-map® Dysbiosis Analyzer software that accompanies the test.

GA-map® Dysbiosis Test Lx Procedure Quick Guide

GA-map Dysbiosis Test

If you have any other questions about these products or our other offerings, contact us here.

Intracerebral hemorrhage (ICH) is caused by bleeding within the brain. Very few circulating biomarkers are known to be associated with the risk of ICH. Fibroblast growth factor 23 is a bone-derived protein hormone associated with mortality in patients with heart failure. A recent nested case–control study showed that Fibroblast growth factor 23 is associated with risk of intracerebral hemorrhage: Fibroblast growth factor 23 is associated with risk of intracerebral hemorrhage. Svensson EH, Söderholm M. Eur J Neurol. 2022 Jan;29(1):114-120. doi: 10.1111/ene.15060. PMID: 34379844.


Background and purpose: Fibroblast growth factor 23 is an osteogenic hormone associated with chronic kidney disease and is an emerging risk factor for several cardiovascular diseases. The association of Fibroblast growth factor 23 (FGF23) with stroke is unclear. The aim of this study was to investigate the association of FGF23 with incident intracerebral hemorrhage (ICH).

Methods: This was a nested case-control study of 220 ICH cases and 244 age- and sex-matched controls from the population-based Malmö Diet and Cancer Study (n = 28,449). Incident ICH cases were ascertained using national registers and classified by bleeding location. Logistic regression was used to study the association of plasma levels of FGF23 with incident ICH, adjusting for potential ICH risk factors. Subgroup analyses were performed for lobar and non-lobar ICH, fatal ICH, ICH with large volume and ICH with poor functional outcome, respectively.

Results: Higher FGF23 levels at baseline were significantly associated with incident ICH. After multivariable adjustment, the odds ratio for the association with all ICH was 1.84 (95% confidence interval [CI] 1.25-2.71, p = 0.002) per doubling of FGF23 concentration. For lobar and non-lobar ICH, odds ratios were 1.73 (95% CI 1.04-2.87, p = 0.035) and 2.13 (95% CI 1.32-3.45, p = 0.002), respectively. FGF23 was also significantly associated with fatal ICH, ICH with large volume and ICH with poor functional outcome.

Conclusions: Higher FGF23 was associated with incident ICH in this nested case-control study. Further studies are required to explore whether the association is causal.

Eagle Biosciences’ FGF23 kits listed below:

FGF23 C-Terminal ELISA Assay Kit
MedFrontier Intact FGF23 Assay

If you have any questions about this items or any of our other offerings, contact us here.

TDM Assay Highlight
Eagle Biosciences is proud to highlight our extensive range of Therapeutic Drug Monitoring (TDM) Assays!

Why use TDM Assays?

TDM Assays for biosimilars and biologics are developed primarily for the studies and development of drugs and vaccines in specific therapeutics and therapeutic pathways. They are utilized by pharmaceutical and biopharmaceutical companies, as well as universities and other researchers to aide in a wide variety of research fields.

About TDM Assays

It has long been acknowledged that data on different drug and target species (e.g., free vs total levels of drug target as two possible biomarkers) may satisfy different needs. Depending on the information required for decision-making, the data required and hence the selection of assay (free, total or both) may differ at each phase of drug development.

Free drug levels reflect the availability of the active drug, while the total or bound drug complex is of importance when checking for efficacy or dynamic interactions of the drug, and for other PK/PD assessments. Thus, it is important to understand the information needed at different stages of drug development.

We offer a wide range of products to measure free and partially bound drug, as well as total drug (free, bound, partially bound), and the bound drug complex.

And we’ll be expanding our extensive line in the future!

If you have any questions about our TDM Assay Kits or our other offerings, contact us here.

GA-map Dysbiosis Test

Understanding the Microbiome with Pioneering Research at Genetic Analysis

Anita Jusnes and Christin Casén of Genetic Analysis AS were recently featured on Dr. Ruscio Radio! They discuss with Dr. Ruscio the GA-Map Dysbiosis Test Lx, the only research dysbiosis index for the gut. The conversation covers topics including but not limited to, how the test came to be, the methodology behind the results, how the test has been validated, and how it can be used to distinguish healthy controls from other samples.

Find the full episode and transcript here.

About the GA-map Dysbiosis Test

The human microbiome market is accelerating both in terms of evidence-based research and pharma products launched. The market’s need for a validated microbiome test is growing. Genetic Analysis AS is at the forefront of this development with the GA-map Dysbiosis Test. The unique, GA-map® Dysbiosis Test, detects and characterizes imbalance in the gut microbiota (dysbiosis) in human fecal samples. All pre-processing of the data is done by the GA-map® Dysbiosis Test analyze software. Reports are automatically generated on the dysbiosis index (DI) and the bacteria abundance. The DI can be customized to your needs. Based on a deviation from a normal reference population, a measure of bacteria abundances and deviations to the references are calculated. The results are presented in an easy to interpret report form, containing the 48 preselected bacteria markers.

Additionally, Genetic Analysis has developed a fecal COVID-19 test that is performed on the same GA-map platform and is an important research tool in the analysis of an individual’s COVID-19 status.

If you have any questions about the GA-map Dysbiosis Test Lx or any of our other offerings, contact us here.

A recent study shows a strong association between the development of hyperphosphatemia in dogs with chronic kidney disease and increased serum levels of fibroblastic growth factor-23 (FGF-23)

Miyakawa H, Hsu H-H, Ogawa M, Akabane R, Miyagawa Y, Takemura N. Association between serum fibroblast growth factor-23 concentration and development of hyperphosphatemia in normophosphatemic dogs with chronic kidney disease. J Vet Intern Med. 2021;35(5):2296-2305. Full Text.


Chronic kidney disease (CKD) is a common, irreversible, and progressive disease in dogs. In patients with CKD, mineral metabolism disorders such as hyperphosphatemia, renal hyperparathyroidism, and decreased calcitriol synthesis also occur because of impaired renal function. These disorders are termed CKD—mineral and bone disorder (MBD). Hyperphosphatemia (abnormally high serum phosphate levels) is known to be a prognostic factor for shorter survival time in dogs with CKD.

The role of FGF-23 in CKD

Fibroblast growth factor-23 is released from osteocytes in response to increased serum phosphorus and calcitriol concentrations and promotes phosphate excretion into the urine by downregulation of the sodium-phosphate co-transporter in renal proximal tubular cells and inhibition of calcitriol synthesis. Fibroblast growth factor-23 acts by binding to the FGF receptor-α-klotho complex.13 In humans, cats, and dogs with CKD, circulating FGF-23 concentrations have been shown to increase in the advanced CKD stages. Increased FGF-23 concentration in CKD patients is associated with various mechanisms, such as a decreased clearance of FGF-23 because of decreasing glomerular filtration rate (GFR), compensation for the accumulation of phosphate in the body, and compensation for decreased klotho protein concentrations. Blood FGF-23 concentrations in dogs with CKD have been shown to become increased earlier than serum phosphorous concentrations therefore, FGF-23 has been noted as an early marker of CKD-MBD.

Researchers hypothesized that FGF-23 predicts development of hyperphosphatemia in normophosphatemic dogs with CKD. If correct, FGF-23 may be a useful marker of when to initiate a phosphate-restricted diet to prevent the development of hyperphosphatemia.

About the MedFrontier Intact FGF23 Assay

  • low sample volume required – only 20ul
  • ONLY assay that measures the full-length active form (intact form) of FGF23
  • superior dynamic range of 10-3000 pg/uL
  • CLEIA technology

The MedFrontier Intact FGF23 Assay was developed and manufactured by Minaris Medical.

IF you have any questions about this product or any of our other products, contact us here.

iLite Assay Ready Cells Product Spotlight

One of our supplier’s was recently featured in an editorial by Select Science! Svar Life Sciences has been working closely with Dr. Erik Tillman at Akero Therapeutics. Tillman and his team are developing a multi-modal drug that could help treat the drivers of non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic related fatty liver disease (NAFLD) that has increased risk for cardiovascular and liver related morbidity and mortality. Him and his team have been working with Svar to create custom iLite assay-ready cells for the cell-based assays that have become a key role in the work Tillman and his teammates perform daily.

“The assay-ready cells have been much more robust and the results have been more reproducible than other cell-based assays that we had tried to use or develop in the past,” says Tillman. “Using the assay-ready cells from Svar, we understand how the cells have been made and characterized, and we are confident in how the cells are going to perform from one vial to the next, and from one lot to the next. Svar’s expertise in the engineering of the cell system and our results thus far have given us the confidence to broaden our use of the assay-ready cells.”

Click here to read the full editorial about Dr. Tillman’s research and the role of Svar’s iLite assay-ready cells.

If you have any questions about Svar’s iLite Assay Ready Cells or our other offerings contact us here.